← All stories

FDA rejects Capricor's Duchenne cell therapy after two failed trials

No. 69·85 words

The Food and Drug Administration said Friday it rejected deramiocel, a cell therapy Capricor Therapeutics developed for Duchenne muscular dystrophy.

The treatment was aimed at teenagers and young men with Duchenne who have already lost the ability to walk. They have few options today. Deramiocel did not help them either. Capricor ran two randomized clinical trials, and neither showed the therapy could stave off heart failure or preserve muscle function in patients' arms.

A public pressure campaign to win approval did not change the outcome.

Discuss on the board

FDA rejects Capricor's Duchenne cell therapy after two failed trials — The Fritter Post